Karin Flicker1, Elisabeth Smolle2, Johannes Haybaeck3, Farid Moinfar4. 1. Institute of Human Genetics, Medical University of Graz, Harrachgasse 21/8, A-8010 Graz, Austria. 2. Institute of Pathology, Medical University of Graz, Auenbruggerplatz 25, A-8036 Graz, Austria. Electronic address: elisabeth.smolle@stud.medunigraz.at. 3. Institute of Pathology, Medical University of Graz, Auenbruggerplatz 25, A-8036 Graz, Austria. Electronic address: johannes.haybaeck@medunigraz.at. 4. Institute of Pathology, Medical University of Graz, Auenbruggerplatz 25, A-8036 Graz, Austria; Institute of Pathology, Hospital of the Sisters of Charity Linz, Linz, Austria.
Abstract
INTRODUCTION: The endometrial stromal sarcoma (ESS) is a very rare uterine sarcoma, counting for 1-3% of all gynecologic malignancies. ESS represents 0.2-8% of all uterine malignant tumors and accounts for about 10% of all uterine sarcomas. With regard to chromosomal aberrations, very little is known about benign and malignant endometrial stromal tumors. METHODS: 30 tumors, consisting of 4 cases of benign endometrial stromal nodule (ESN), 22 cases of low-grade ESS and 4 cases of undifferentiated endometrial sarcoma (UES), were analyzed by array-comparative genomic hybridization (aCGH). RESULTS: ESN did not show many copy number changes (CNCs) by aCGH. Frequent losses could be identified on chromosomes 7p and 19, and gains on chromosomes 1q, 6p and 8q. Low-grade ESS presented as a very heterogeneous group. 90% (20/22) of cases displayed aberrations. Most frequent changes were losses on chromosomes 7 and 22, and gains on chromosome 1q or 11. UES showed a high number of chromosomal aberrations and on every chromosome CNCs were detected. Most frequent changes were losses on chromosomes 1q, 2q (3/4, 75%) and 13, and gains on chromosomes 1q and 17p. CONCLUSION: Our data shows an increasing number of CNCs from ESN to low-grade ESS and to UES. However, the chromosomal aberrations differ considerably between the investigated ESN-, low-grade ESS- and UES cases and thus, a linear tumor progression seems to be unlikely.
INTRODUCTION: The endometrial stromal sarcoma (ESS) is a very rare uterine sarcoma, counting for 1-3% of all gynecologic malignancies. ESS represents 0.2-8% of all uterine malignant tumors and accounts for about 10% of all uterine sarcomas. With regard to chromosomal aberrations, very little is known about benign and malignant endometrial stromal tumors. METHODS: 30 tumors, consisting of 4 cases of benign endometrial stromal nodule (ESN), 22 cases of low-grade ESS and 4 cases of undifferentiated endometrial sarcoma (UES), were analyzed by array-comparative genomic hybridization (aCGH). RESULTS: ESN did not show many copy number changes (CNCs) by aCGH. Frequent losses could be identified on chromosomes 7p and 19, and gains on chromosomes 1q, 6p and 8q. Low-grade ESS presented as a very heterogeneous group. 90% (20/22) of cases displayed aberrations. Most frequent changes were losses on chromosomes 7 and 22, and gains on chromosome 1q or 11. UES showed a high number of chromosomal aberrations and on every chromosome CNCs were detected. Most frequent changes were losses on chromosomes 1q, 2q (3/4, 75%) and 13, and gains on chromosomes 1q and 17p. CONCLUSION: Our data shows an increasing number of CNCs from ESN to low-grade ESS and to UES. However, the chromosomal aberrations differ considerably between the investigated ESN-, low-grade ESS- and UES cases and thus, a linear tumor progression seems to be unlikely.
Authors: Joanna Przybyl; Magdalena Kowalewska; Anna Quattrone; Barbara Dewaele; Vanessa Vanspauwen; Sushama Varma; Sujay Vennam; Aaron M Newman; Michal Swierniak; Elwira Bakuła-Zalewska; Janusz A Siedlecki; Mariusz Bidzinski; Jan Cools; Matt van de Rijn; Maria Debiec-Rychter Journal: JCI Insight Date: 2017-06-02
Authors: Youn Jin Choi; Seung-Hyun Jung; Min Sung Kim; In-Pyo Baek; Jae-Keun Rhee; Sung Hak Lee; Soo Young Hur; Tae-Min Kim; Yeun-Jun Chung; Sug Hyung Lee Journal: Oncotarget Date: 2015-10-20
Authors: Francesca Micci; Ludmila Gorunova; Antonio Agostini; Lene E Johannessen; Marta Brunetti; Ben Davidson; Sverre Heim; Ioannis Panagopoulos Journal: Genes Chromosomes Cancer Date: 2016-08-09 Impact factor: 5.006